312 related articles for article (PubMed ID: 21263462)
21. Signaling through RIG-I and type I interferon receptor: Immune activation by Newcastle disease virus in man versus immune evasion by Ebola virus (Review).
Schirrmacher V
Int J Mol Med; 2015 Jul; 36(1):3-10. PubMed ID: 25998621
[TBL] [Abstract][Full Text] [Related]
22. MAVS-dependent IRF3/7 bypass of interferon β-induction restricts the response to measles infection in CD150Tg mouse bone marrow-derived dendritic cells.
Takaki H; Honda K; Atarashi K; Kobayashi F; Ebihara T; Oshiumi H; Matsumoto M; Shingai M; Seya T
Mol Immunol; 2014 Feb; 57(2):100-10. PubMed ID: 24096085
[TBL] [Abstract][Full Text] [Related]
23. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35.
Leung DW; Prins KC; Borek DM; Farahbakhsh M; Tufariello JM; Ramanan P; Nix JC; Helgeson LA; Otwinowski Z; Honzatko RB; Basler CF; Amarasinghe GK
Nat Struct Mol Biol; 2010 Feb; 17(2):165-72. PubMed ID: 20081868
[TBL] [Abstract][Full Text] [Related]
24. Ebola virus VP35 perturbs type I interferon signaling to facilitate viral replication.
Cao Z; Liu C; Peng C; Ran Y; Yao Y; Xiao G; Li E; Chen Z; Chuai X; Chiu S
Virol Sin; 2023 Dec; 38(6):922-930. PubMed ID: 37839549
[TBL] [Abstract][Full Text] [Related]
25. Cynarin blocks Ebola virus replication by counteracting VP35 inhibition of interferon-beta production.
Corona A; Fanunza E; Salata C; Morwitzer MJ; Distinto S; Zinzula L; Sanna C; Frau A; Daino GL; Quartu M; Taglialatela-Scafati O; Rigano D; Reid S; Mirazimi A; Tramontano E
Antiviral Res; 2022 Feb; 198():105251. PubMed ID: 35066016
[TBL] [Abstract][Full Text] [Related]
26. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.
Hartman AL; Dover JE; Towner JS; Nichol ST
J Virol; 2006 Jul; 80(13):6430-40. PubMed ID: 16775331
[TBL] [Abstract][Full Text] [Related]
27. Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function.
Prins KC; Binning JM; Shabman RS; Leung DW; Amarasinghe GK; Basler CF
J Virol; 2010 Oct; 84(20):10581-91. PubMed ID: 20686031
[TBL] [Abstract][Full Text] [Related]
28. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3.
Basler CF; Mikulasova A; Martinez-Sobrido L; Paragas J; Mühlberger E; Bray M; Klenk HD; Palese P; García-Sastre A
J Virol; 2003 Jul; 77(14):7945-56. PubMed ID: 12829834
[TBL] [Abstract][Full Text] [Related]
29. Ebolavirus VP35 is a multifunctional virulence factor.
Leung DW; Prins KC; Basler CF; Amarasinghe GK
Virulence; 2010; 1(6):526-31. PubMed ID: 21178490
[TBL] [Abstract][Full Text] [Related]
30. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1.
Prins KC; Cárdenas WB; Basler CF
J Virol; 2009 Apr; 83(7):3069-77. PubMed ID: 19153231
[TBL] [Abstract][Full Text] [Related]
31. Balance of power in host-virus arms races.
Kok KH; Jin DY
Cell Host Microbe; 2013 Jul; 14(1):5-6. PubMed ID: 23870307
[TBL] [Abstract][Full Text] [Related]
32. Structural basis for Marburg virus VP35-mediated immune evasion mechanisms.
Ramanan P; Edwards MR; Shabman RS; Leung DW; Endlich-Frazier AC; Borek DM; Otwinowski Z; Liu G; Huh J; Basler CF; Amarasinghe GK
Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20661-6. PubMed ID: 23185024
[TBL] [Abstract][Full Text] [Related]
33. Lloviu virus VP24 and VP35 proteins function as innate immune antagonists in human and bat cells.
Feagins AR; Basler CF
Virology; 2015 Nov; 485():145-52. PubMed ID: 26255028
[TBL] [Abstract][Full Text] [Related]
34. TRAF6 establishes innate immune responses by activating NF-kappaB and IRF7 upon sensing cytosolic viral RNA and DNA.
Konno H; Yamamoto T; Yamazaki K; Gohda J; Akiyama T; Semba K; Goto H; Kato A; Yujiri T; Imai T; Kawaguchi Y; Su B; Takeuchi O; Akira S; Tsunetsugu-Yokota Y; Inoue J
PLoS One; 2009 May; 4(5):e5674. PubMed ID: 19479062
[TBL] [Abstract][Full Text] [Related]
35. dsRNA binding characterization of full length recombinant wild type and mutants Zaire ebolavirus VP35.
Zinzula L; Esposito F; Pala D; Tramontano E
Antiviral Res; 2012 Mar; 93(3):354-63. PubMed ID: 22289166
[TBL] [Abstract][Full Text] [Related]
36. Human Plasmacytoid and Monocyte-Derived Dendritic Cells Display Distinct Metabolic Profile Upon RIG-I Activation.
Fekete T; Sütö MI; Bencze D; Mázló A; Szabo A; Biro T; Bacsi A; Pazmandi K
Front Immunol; 2018; 9():3070. PubMed ID: 30622542
[TBL] [Abstract][Full Text] [Related]
37. Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity.
Fournier P; Arnold A; Wilden H; Schirrmacher V
Int J Oncol; 2012 Mar; 40(3):840-50. PubMed ID: 22102168
[TBL] [Abstract][Full Text] [Related]
38. The Ebola Interferon Inhibiting Domains Attenuate and Dysregulate Cell-Mediated Immune Responses.
Lubaki NM; Younan P; Santos RI; Meyer M; Iampietro M; Koup RA; Bukreyev A
PLoS Pathog; 2016 Dec; 12(12):e1006031. PubMed ID: 27930745
[TBL] [Abstract][Full Text] [Related]
39. The Host E3-Ubiquitin Ligase TRIM6 Ubiquitinates the Ebola Virus VP35 Protein and Promotes Virus Replication.
Bharaj P; Atkins C; Luthra P; Giraldo MI; Dawes BE; Miorin L; Johnson JR; Krogan NJ; Basler CF; Freiberg AN; Rajsbaum R
J Virol; 2017 Sep; 91(18):. PubMed ID: 28679761
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex.
Rodriguez-Madoz JR; Belicha-Villanueva A; Bernal-Rubio D; Ashour J; Ayllon J; Fernandez-Sesma A
J Virol; 2010 Oct; 84(19):9760-74. PubMed ID: 20660196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
